MedTrace Logo

Comparing the Adaptation of Commercial Milk and A2 Milk in Lactose Maldigesters

NCT05669274 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2023-03-30

No results posted yet for this study

Summary

Cow's milk contains two types of β-casein: A1 and A2. It is evident from human clinical trials that milk with A1 protein produces more hydrogen and symptoms of lactose intolerance. A pro-inflammatory μ-opioid peptide BCM-7 is released from A1 but not from A2. Milk containing A1 β-casein produced more inflammatory markers than A2 β-casein. This is a double-blinded, randomized, controlled trial conducted to determine if there are changes in inflammatory markers following two weeks of milk feeding, due to milk containing A1 and A2 beta-casein as compared to milk containing only A2 beta-casein.

Conditions

  • Lactose Intolerance

Interventions

OTHER

Milk containing A1 and A2 beta-casein

Milk dose for 2 weeks

OTHER

Milk containing only A2 beta-casein

Milk dose for 2 weeks

Sponsors & Collaborators

  • Purdue University

    lead OTHER

Principal Investigators

  • Dennis Savaiano, PhD · Purdue University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-02
Primary Completion
2024-12-06
Completion
2025-12-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05669274 on ClinicalTrials.gov